In Brief
Targeting the potent homologous toxins of Clostridium difficile is a promising therapeutic approach to treat the symptoms associated with infection. Tam et al. describe the identification of the first small molecule inhibitors that protect human cells by blocking receptor binding and directly inhibiting toxin enzyme activity.
INTRODUCTION
Clostridium difficile is the leading cause of hospital-acquired infectious diarrhea and antibiotic-associated pseudomembranous colitis. C. difficile infections (CDIs) are almost always triggered by alterations in the endogenous gastrointestinal flora in patients taking broad-spectrum antibiotic treatments (Bartlett, 2002) . The current treatment strategies for patients with symptomatic C. difficile are either to remove the offending antibiotic to encourage reestablishment of healthy gut flora, or, contrariwise, to administer additional antibiotics such as metronidazole, vancomycin, and/or fidaxomicin to eradicate the pathogen (Cohen et al., 2010; Venugopal and Johnson, 2012) . Neither of these approaches addresses the acute and chronic effects of the secreted toxins on the gut during CDI. Moreover, increasing treatment failure and relapse rates in patients, along with the threat of resistance against current antibiotics, underscore the need to search for therapies that neutralize toxin function (Kelly and LaMont, 2008) .
Pathogenic strains of C. difficile elaborate defined combinations of two homologous toxins, TcdA and TcdB, and a binary toxin called CDT. Extensive experimental and epidemiological evidence indicates that TcdB and TcdA are the primary determinants of virulence (Kuehne et al., 2010; Lyras et al., 2009) , while CDT appears to contribute to disease when present (Kuehne et al., 2014) . TcdA and TcdB are large four-domain toxins sharing 49% sequence identity and 63% sequence similarity ( Figure 1A) . Both toxins enter cells by clathrin-mediated endocytosis (Papatheodorou et al., 2010) , whereupon organelle acidification leads to conformational changes that result in the creation of a transmembrane pore (Qa'dan et al., 2005; Zhang et al., 2014 ) and delivery of the N-terminal autoprocessing cysteine protease domain (CPD) and glucosyltransferase domains (GTD) into the cytosol. Allosteric activation of the CPD by intracellular inositol hexakisphosphate (IP 6 ) induces release of the GTD into the cytosol (Pruitt et al., 2009) , which inactivates small Rho-family GTPases involved in regulating actin dynamics (Just et al., 1995a (Just et al., , 1995b . Inactivation of Rho proteins leads to the loss of structural integrity of the cell as a consequence of F-actin effects resulting from dysregulation of actin depolymerization (Voth and Ballard, 2005) . Loss of cell integrity and the consequent cell rounding precede apoptosis and finally death of the intoxicated cell, which is thought to occur via a caspase-3and caspase-9-dependent pathway (Hippenstiel et al., 2002) . Significantly, despite sharing similar structures and mechanisms of cellular intoxication, TcdB is at least 100-fold more potent than TcdA in its ability to induce cell rounding and apoptotic cell death in various cell types (Chaves-Olarte et al., 1997; Donta et al., 1982) .
Functional studies using domain-inactivating mutants and truncations have established that the cytopathic and cytotoxic effects of toxins on cells require an enzymatically active GTD and a pore formation competent delivery domain (Faust et al., 1998; Genisyuerek et al., 2011; Hofmann et al., 1997; Jank et al., 2007; Zhang et al., 2013 Zhang et al., , 2014 . The CPD activity and C-terminal CROPs domains, although important for full toxicity, appear to not be essential for cellular intoxication, as inactivation or removal of either domain yields toxin variants that are just 10to 100-fold less toxic to cells (Gerhard et al., 2013; Kreimeyer et al., 2011; Li et al., 2013; Olling et al., 2011) . Distinct from the potent cytopathic/cytotoxic effects that are observed at subpicomolar to low picomolar concentrations of TcdB, it was shown recently that higher concentrations of TcdB (i.e., $100to 1,000-fold higher than required for cell rounding) induced NADPH oxidase-mediated necrosis in target cells (Chumbler et al., 2012; Farrow et al., 2013; Wohlan et al., 2014) . Surprisingly, this phenotype was found to be independent of both CPD and GTD activity, depending primarily on a pore formation competent delivery domain (Zhang et al., 2014) , and presumably an intact receptor binding moiety. Although the physiological relevance of this phenotype remains to be validated, that the concentrations required to induce this phenotype correlate with pathology in a model of epithelial damage (Chumbler et al., 2012) suggests that this phenotype may be important, perhaps in fulminant infection, where much higher doses of toxin may be reached.
In this study, we set out to identify therapeutic strategies to neutralize the actions of TcdB on cells using chemical libraries composed of diverse small molecules. With four potential toxin domains and several host pathways and processes to target ( Figure 1A) , the question arises: which targeting strategy is the best? To address this, we used a chemical genetics strategy that allowed us to probe all targets and pathways simultaneously to identify the most drug-sensitive targets and nodes to target using small molecules. Using this approach, we report the identification of several small molecules capable of protecting cells from TcdB-induced rounding, including toxin-modifying compounds, a toxin-stabilizing molecule, inhibitors of endosomal acidification, and noncompetitive inhibitors of GTD activity. Using mechanistically distinct classes of inhibitors, we further demonstrate distinct outcomes of targeting cell rounding versus necrosis. These findings form the basis for linking the functional importance of each domain and targeting step with respect to a given phenotype and provide a foundation for developing the first-generation inhibitors targeting the highly pathogenic toxins of C. difficile.
RESULTS

Phenotypic HTS for Inhibitors of TcdB-Induced Cell Rounding
To enable screening of chemical libraries, a robust highthroughput assay of cell rounding was developed using a highcontent imaging platform that could track changes in several (Bottom) A cartoon depicting the stepwise mechanism of target cell intoxication by TcdA and TcdB that leads to cell rounding (see Introduction for details). (B) Representative images from wells of a 96-well plate of untreated (top) and TcdB-treated (bottom) IMR-90 cells 3 hr post treatment taken with a Cellomics ArrayScan VTI reader using a 103 objective. Blue outlines denote the CellTracker-labeled cells identified by the target acquisition algorithm for the quantification of cellular morphology. (C) Quantification of changes in cell area, A, LWR, and (LWR 3 A), which we defined here as the CRI. Results ± SEM are the average of three independent experiments. (D) Titration of TcdB on human IMR-90 cells (n = 3; showing SEM) identifies a dose of toxin where 99% of cells were rounded; i.e., EC 99 = 10 pM. (E) High-throughput phenotypic screening data. Each square represents inhibition of cell rounding for a given compound tested at 40 mM. The dashed line represents the calculated hit cutoff (3s = 39%). A histogram (right) shows the distribution of compounds (in 5% bins) with respect to inhibition of rounding.
indices of cell morphology in response to TcdB treatment (Figure S1 available online). TcdB-induced changes to cell area and the length to width ratio (LWR) were found to be the most pronounced and statistically robust parameters ( Figures 1B  and 1C ). The product of these two parameters yielded what we define here as the cell-rounding index (CRI), which gave HTS-compatible Z 0 factors >0.55 in either 96-or 384-well formats. For screening, human-derived IMR-90 fibroblasts were pretreated with compound (final concentration = 40 mM) for 10 min, followed by treatment with a concentration of TcdB that resulted in $99% of cells becoming rounded after 3 hr at 37 C (viz., EC 99 = 10 pM; Figure 1D ). A small molecule chemical library consisting of natural products, drugs approved for human use, and molecules with known biological activity was screened ( Figure 1E ). In this screen, 66 compounds protected cells by greater than three SDs above the library mean, corresponding to an inhibition of CRI = 39%, of which 29 confirmed, yielding an adjusted hit rate of 1.25%.
Nonselective Inhibitors of TcdB-Induced Cell Rounding
To identify and flag hits acting through nonspecific, promiscuous, or otherwise undesirable mechanisms, we used general filters to hits in addition to the more detailed studies. These filters proved to be critical for correctly elucidating the mechanism of action for certain hits and removing others. In particular, two hits, epigallocatechin-3-monogallate (EGCG) and theaflavin monogallate (TG), structural analogs from tea, were found during initial characterization to inhibit TcdB glucosyltransferase activity. We discovered, however, that small amounts of Triton X-100 in the reaction mixture significantly reduced their potency, hallmarks of a promiscuous aggregation mode of binding and inhibition (Feng and Shoichet, 2006 ) ( Figure S2 ). More dramatically, we found that incubating TcdB with either EGCG or TG resulted in the formation of TcdB aggregates that persisted on SDS-PAGE. Moreover, using the unrelated human Rac-1 GTPase protein as a control, we observed a similar induction of SDS-resistant aggregates ( Figure S2 ).
Multiple Inhibitors of Endosomal Acidification Prevent Toxin Translocation
Following uptake of TcdB, the cytotoxic GTD must be delivered across the endosomal membrane. Endosomal acidification induces conformational changes in TcdB that result in the creation of a pore through which the GTD can pass (Zhang et al., 2014) . Agents that inhibit endosome-lysosome acidification, such as the general v-ATPase inhibitor bafilomycin A1, or the lysosomotropic weak base ammonium chloride, can therefore indirectly neutralize TcdB toxicity by preventing pore formation and translocation (Qa'Dan et al., 2000) . In the presence of bafilomycin A1, cells were completely protected from TcdB-induced rounding (Figure 2A ).
To identify whether any hits protected cells from TcdB by inhibiting endosomal acidification, we tested for their ability to competitively reduce accumulation of the pH-sensitive fluorescent dye LysoTracker red within acidic organelles. Preincubation of cells with bafilomycin A1 prior to addition of LysoTracker red largely ablated endosomal/lysosomal staining as observed by fluorescence microscopy ( Figure 2B ). Using a recently described plate-based modification of this protocol (Slater et al., 2013), we quantified LysoTracker staining in the presence of each hit ( Figure 2C ). Among the hits that protected cells from TcdB intoxication, we found several that significantly inhibited LysoTracker staining to levels similar to bafilomycin, including the carboxylic ionophore monensin and a number of other compounds with characteristic lysosomotropic features (i.e., weakly basic amines), such as aminacrine, amodiaquine, quinacrine, and prazosin (de Duve et al., 1974) ( Figure 2C ). Using the antimalarial drug quinacrine (the most potent inhibitor of cell rounding), we confirmed that the extent of inhibition of LysoTracker staining tracked closely with the extent inhibition of TcdB-induced cell rounding ( Figure 2D ).
Conformational Stabilization of TcdB by Methyl Cholate Prevents Toxicity
A hit with a unique profile that was identified here was the bile acid derivative methyl cholate. Of the 12 bile acid analogs that were tested, methyl cholate was the most potent, and in fact the only one that was identified as a hit in the primary screen ( Figure 3A ). Notably, a number of close analogs of methyl cholate with subtle changes in some cases were either only partially active (i.e., methyldeoxycholate), or completely inactive (i.e., cholic acid), suggesting a degree of specificity for methyl cholate. Next, we tested the selectivity of methyl cholate for TcdB over TcdA. Remarkably, we observed virtually no inhibition of TcdA-induced cell rounding over doses at which we see complete protection of the more potent TcdB ( Figure 3B ). Given this profile, we reasoned that methyl cholate was not likely inhibiting a general host target or process common to TcdA and TcdB, but rather likely interacting directly with TcdB. To test this, we first tested the thermal stability of TcdB in the absence and presence of increasing doses of methyl cholate and cholic acid using differential scanning fluorimetry (Niesen et al., 2007) ( Figure 3C ). Methyl cholate, and not cholic acid, induced a robust increase in the thermal stability of TcdB; the melting temperature (T m ) of TcdB dose dependently increased from 49 C in DMSO to 55 C in the presence of methyl cholate ( Figure 3C ). No change in stability was observed for TcdA (data not shown).
To characterize the mechanism of methyl cholate neutralization of TcdB further, we next assayed the relevant functions of the individual toxin domains in the presence of methyl cholate. The GTD, which catalyzes the transfer of a glucose moiety from UDP-glucose to an Rac1-GTPase acceptor, was not inhibited by methyl cholate using the in vitro Western blot assay ( Figure 3D ). By contrast, methyl cholate dose dependently inhibited IP 6 -induced autoprocessing of full-length TcdB (Figure 3E) . Unexpectedly, this inhibition was seen only in the context of the holotoxin; no inhibition of autoprocessing by methyl cholate was evident in a truncated construct (i.e., GTD-CPD), indicating that the methyl cholate binding site was either disrupted in the context of the truncation or was outside the CPD ( Figure 3E) . Remarkably, when we tested the effect of methyl cholate on receptor binding, we saw a dramatic decrease in the amount of toxin bound to cells. Methyl cholate, but not cholic acid, inhibited TcdB binding to cells to a similar extent to the neutralizing monoclonal antibody bezlotoxumab (Orth et al., 2014) ( Figure 3F ). These data indicate that methyl cholate binds at a site unique to TcdB and induces a conformational change/stabilization of TcdB that prevents autoactivation and receptor binding to target cells.
Phloretin Is a Direct Noncompetitive Inhibitor of Toxin GTD Activity A novel hit from the primary screen that was of considerable interest was the naturally occurring flavonoid phloretin, which protected cells from both TcdA-and TcdB-induced cell rounding ( Figure 4A ). We discovered through subsequent characterization that phloretin was a direct inhibitor of the toxin GTD domain, as it dose dependently inhibited glucosylation of GST-Rac1 using the in vitro Western blot assay ( Figure 4B ). To explore the mode of inhibition further, we designed a novel scintillation proximity assay (SPA) of glucosyltransferase activity using 3 H-labeled UDP-glucose to monitor GST-Rac1 glucosylation. In parallel, we used a bioluminescent UDP detection assay (Promega) to monitor UDP-glucose hydrolysis by the GTD in the absence of GST-Rac1. Using these assays, we showed that phloretin dose dependently inhibited both transferase and hydrolase activities of the isolated GTD, albeit with differential potency, having IC 50 values of 2.1 and 207.1 mM, respectively ( Figure 4C ).
Kinetic analysis of the inhibition of hydrolase activity by phloretin demonstrated a marked reduction in reaction maximal velocity (V max ), while having no effect on the K m with respect to UDP-glucose ( Figure 4D ). This kinetic pattern is a hallmark of a noncompetitive mode of inhibition. This is well illustrated by the Hanes-Woolf transformation, where the x intercept represents ÀK m and 1/V max represents the slope of the line. For a noncompetitive inhibitor, lines on a Hanes-Woolf plot will converge on the x axis, as observed for phloretin ( Figure 4D) .
A closer look at the primary screening results as a whole revealed the presence of additional phloretin-like analogs, some of which were just below the hit cutoff line and others that were inactive. Encouraged by the potential to identify additional and potentially more potent noncompetitive analogs of phloretin, we screened a focused library containing 500 natural and synthetic flavonoid derivatives using the cell-rounding phenotypic assay ( Figure S3 ). We identified two compounds of particular interest: a chalcone derivative of phloretin called ST031321 ( Figure 4E ), which partially protected cells from cell rounding, and a more potent synthetic flavan analog of phloretin called ST075672, which completely protected cells from TcdAand TcdB-induced rounding ( Figure 4F ). ST075672 was found to inhibit both glucosyltransferase and hydrolase activity with an IC 50 of 7.7 and 38.9 mM, respectively.
Mechanism-Specific Inhibition of TcdB-Induced Necrosis
At higher doses of TcdB, cells undergo a rapid necrotic-like cell death via an NADPH oxidase pathway, characterized by a rapid depletion of ATP, loss of membrane integrity, lack of caspase-3/ 7 activation, and rapid lactate dehydrogenase release (Farrow et al., 2013) . This alternative phenotype was recently shown to require a pore formation competent delivery domain (Zhang et al., 2014) but not GTD or CPD activities (Chumbler et al., 2012) , suggesting that the host and toxin factors responsible for mediating cell rounding and cellular necrosis, although overlapping, are distinct. Using the mechanistically distinct inhibitors that were uncovered here, we asked whether and to what extent different targeting strategies inhibited TcdB-mediated necrosis. The antimalarial drug quinacrine, which inhibits endosomal acidification, was a robust inhibitor of TcdB-induced necrosis (Figure 5A) , further reinforcing the importance of pore formation in mediating the necrosis phenotype (Zhang et al., 2014) . Interest-ingly, methyl cholate, which blocks both CPD autoactivation and receptor binding, inhibited the CPD-independent necrosis phenotype ( Figure 5B) , consistent with the notion that inhibition of receptor binding is likely responsible for the observed neutralization. Last, the noncompetitive inhibitor phloretin was unable to inhibit TcdB-induced necrosis, as would be expected for a pure inhibitor of the GTD ( Figure 5C ).
DISCUSSION
Antibiotic resistance is eroding the efficacy of front-line agents used to treat and control many infectious diseases. Along with continuing to search for new antibiotics, there is a pressing need to identify agents that inhibit bacterial pathogenesis in different ways, such as by targeting the resistance mechanisms directly (King et al., 2014; Leigh et al., 1981) , or by inhibiting the virulence factors that pathogens use to establish infection and mediate disease (Cathcart et al., 2009; Hung et al., 2005; Lyon et al., 2000) . For CDIs where antibiotics are a major contributing factor leading to disease and toxins are the primary determinants of disease, the rationale for developing toxin-targeted therapies is clear. Indeed, a number of large molecule toxin-neutralizing approaches for CDI are being explored in the clinic, including injectable monoclonal antibodies (Lowy et al., 2010 ) (in phase 3 for prevention of CDI recurrence) and toxoid vaccines (Foglia et al., 2012 ) (entering phase 3 for prevention of first episode of CDI). There remains a significant unmet need, however, for orally bioavailable inhibitors of toxin action (i.e., small molecules) as a safe and convenient therapeutic option for patients with mild to severe toxigenic CDI. Importantly, in contrast with biologicsbased antitoxin candidates, which act exclusively by blocking the initial binding to target cells, small molecules provide an opportunity to probe a greater array of toxin and host factors known to be essential for TcdA and TcdB intoxication ( Figure 1A) .
In this study, we used a phenotypic screening approach to identify the first generation of small molecules that protect cells from the potent glucosylating toxins from C. difficile. We identified a structurally diverse set of compounds that protected cells from TcdB-induced cell rounding through correspondingly diverse sets of mechanisms. As with any such phenotypic screening follow-up cascade, elucidating the precise mechanism of action required the development of several specific and general assays that flag spurious promiscuous binders. This was exemplified by the two natural trihydroxyphenyl compounds from tea that have been linked to a number of health benefits through their interactions with various protein targets (Mori et al., 2010; Palhano et al., 2013; Rambold et al., 2008) . Autooxidation of the gallyl and gallate moieties within EGCG and TG can create reactive species that react with cysteine thiol groups (Ishii et al., 2008) and/or free amines in proteins (Palhano et al., 2013) . We saw evidence of this on SDS-PAGE and found that the binding of these compounds was promiscuous, further limiting their value as leads or as tool compounds.
A remarkable and essential feature of many bacterial toxins is their capacity to undergo major conformational changes in response to acidic pH that enable pore formation and translocation into the cytosol. Agents that prevent endosome-lysosome acidification, such as the v-ATPase inhibitor bafilomycin A1 or the lysosomotropic weak base ammonium chloride consequently prevent these conformational steps that lead to intoxication (Qa'Dan et al., 2000) . Here, we identified a number of compounds that inhibited endosomal acidification, including a set of antimalarial compounds and the antihypertensive drug prazosin. Although known to be a highly effective means to neutralize pH-dependent toxins in vitro (Gillespie et al., 2013; Slater et al., 2013; Stechmann et al., 2010) , it remains to be addressed clinically whether a mechanism-based endosomal modifier can be developed with a suitable therapeutic window clinically. Nevertheless, the efficacy of these compounds on both TcdB-induced cell rounding and necrosis provides opportunities to use these compounds and their derivatives to probe specific aspects of toxin pathogenesis in vitro and potentially in vivo.
Phenotypic screening studies aimed at identifying small molecule inhibitors against other toxins, such as ricin, shiga-like toxin, and anthrax, have identified molecules that largely targeted host factors and processes (Gillespie et al., 2013; Slater et al., 2013; Stechmann et al., 2010) . In this study, we identified two distinct direct inhibitors of toxin action. Our initial assignment of the mechanism of the bile acid derivative methyl cholate as a CPD inhibitor was puzzling. Finding a CPD inhibitor that protected cells from TcdB was unexpected given the reported modest impact that inactivating the CPD had on toxin potency Olling et al., 2012) . Subsequent characterization of methyl cholate, however, revealed several important findings that argue that CPD inhibition is indirect and likely not responsible for the effects seen on cells. Chief among these was the observed robust inhibition of receptor binding by methyl cholate to levels similar to the neutralizing monoclonal antibody bezlotoxumab (Orth et al., 2014) . That methyl cholate was unable to inhibit a truncated construct containing GTD-CPD combined with the observed inhibition of the CPD-independent necrosis phenotype further indicates that inhibition of receptor binding was responsible for the observed cellular protection. Another interesting aspect of methyl cholate was the apparent selectivity over TcdA. Future structural studies aimed at determining the precise binding site on TcdB and how this binding affects CPD activity, and more importantly receptor binding, are needed to elucidate the detailed molecular mechanism of inhibition.
The second toxin-targeted compound discovered in this study was the naturally occurring flavonoid phloretin. In contrast with methyl cholate, phloretin inhibited both TcdB and TcdA with approximately equal efficacy. The discovery that phloretin inhibited GTD activity using the low-throughput, semiquantitative Western blot assay prompted us to use alternative approaches that were more amenable to kinetic characterization to uncover the mode of inhibition. Using assays of glucosyltransferase and hydrolase activity, we discovered that phloretin was a noncompetitive inhibitor of the GTD. Although not anticipated, this may reflect that the high intracellular UDP-glucose levels in cells that may disfavor inhibitors are competitive with UDP-glucose. An important feature of noncompetitive enzyme inhibitors is that they can, in principle, achieve high selectivity over other enzymes that utilize the same substrate or reaction mechanism. Given the large number of human enzymes using UDP-glucose as a substrate, this may be a critical factor for enabling selectivity and safety of such inhibitors in the future. The lack of inhibition of necrosis (as would be expected for a GTD inhibitor) also points to future experiments aimed at pharmacological validation of the importance of these distinct phenotypes in vivo.
While the mechanisms described herein await future in vivo characterization for validation, these first-generation inhibitors and their mechanisms nevertheless provide a wealth of information regarding the pathogenesis and future treatment of CDI. In particular, the compounds described herein offer an opportunity to probe the relative importance of the two distinct phenotypes pharmacologically in an in vivo setting.
SIGNIFICANCE
C. difficile is now the leading cause of antibiotic-associated infection in hospitals worldwide. Pathogenic strains produce two homologous toxins, TcdA and TcdB, which cause damage to the cells lining the colon, leading to fluid secretion, tissue damage, and in some cases death. Recently, more virulent strains of C. difficile have emerged characterized by greater antibiotic resistance and increased toxin secretion, leading to a rise in the incidence and severity of disease. In this study, we discovered small molecules capable of protecting human cells from toxin damage. These molecules and the mechanisms by which they act form the foundation for developing the first generation of safe and effective therapies to prevent the devastating effects of toxins in patients suffering from infection.
EXPERIMENTAL PROCEDURES
Cell Lines, Consumables, and Reagents Plasticware used for cell culture and enzyme assays was purchased from Corning. Streptavidin Hi-bind plates, Superblock buffer, SuperSignal West, and Quantablu peroxidase substrate were purchased from Thermo Pierce. Cell lines CHO-k1, Vero, and IMR-90 were from ATCC. Anti-Rac1 antibody Mab102 was from BD Biosciences, and anti-GST antibody was from Genscript. Anti-mouse conjugated peroxidase antibody was from GE Healthcare. The Spectrum library, consisting of 2,320 individual compounds formatted as 10 mM solutions in DMSO, was purchased from MicroSource. The Flav500 (TimTec library) was purchased from Sigma-Aldrich.
Protein Expression and Purification
Plasmid pHis1522 encoding his-tagged TcdB was a kind gift from Hanping Feng; expression and isolation of recombinant TcdB was as described by Yang et al. (2008) . Briefly, transformed Bacillus megaterium was inoculated into LB containing tetracycline and grown to an A600 of 0.7, followed by overnight xylose induc-tion at 37 C. Bacterial pellets were collected, resuspended with 20 mM Tris (pH 8)/0.5 M NaCl, and passed twice through an EmulsiFlex C3 microfluidizer (Avestin) at 15,000 psi, then clarified by centrifuging for 18,000 3 g for 20 min. TcdB was purified by nickel affinity chromatography followed by anion exchange chromatography using HisTrap FF and HiTrap Q columns (GE Healthcare), respectively. Fractions containing TcdB were verified by SDS-PAGE, then pooled and diafiltered with a 100,000 MWCO ultrafiltration device (Corning) into 20 mM Tris (pH 7.5)/150 mM NaCl. Finally, glycerol was added to 15% v/v, the protein concentration was estimated by A280 (using coefficient 288160), divided into single use aliquots, and stored at À80 C.
The regions encoding TcdB A (glucosyltransferase) and AC (glucosyltransferase + cysteine protease) domains were cloned into pET28 vectors and expressed as His-tagged proteins in Escherichia coli BL21 DE3. Induction of expression was initiated with 0.5 mM isopropyl b-d-1-thiogalactopyranoside (IPTG) for 3 hr. Cell lysates were prepared as described for full-length TcdB, and purification of the protein was by nickel affinity chromatography using HisTrap FF columns.
The pGEX-Rac1 plasmid (Addgene plasmid 12200) for expression of GST-Rac1 protein was previously described by Bagrodia et al. (1995) and obtained from Addgene. The plasmid was transformed into E. coli BL21 DE3, and recombinant protein expression was achieved by induction of the culture with 0.1 mM IPTG for 5 hr at 30 C. The cell pellet was recovered by centrifugation, resuspended with 5 ml/g of pellet in 20 mM Tris (pH 7.5)/150 mM NaCl, and sonicated. The cell lysate was clarified by centrifugation, and the GST fusion protein was purified by chromatography through a GSTrap Fast Flow column (GE Healthcare). Following elution with 10 mM glutathione, fractions containing purified protein were pooled and stored at -80 C in the presence of 15% v/v glycerol.
ArrayScan High-Content Phenotypic Screen IMR-90 cells were grown in EMEM (Wisent) supplemented with 10% FBS and penicillin-streptomycin (complete EMEM) and were seeded in 96-well CellBIND plates (Corning) at a density of 8,000-10,000 cells/well. The next day, the medium was exchanged with serum-free EMEM (SFM) containing 1 mM CellTracker Orange CMRA (Molecular Probes). After 60 min, excess dye was removed by medium exchange with SFM. An Agilent Bravo liquid handler was used to deliver 0.4 ml of compound from the MicroSource library plate to the cell plate, immediately followed by 10 ml of 100 pM TcdB (diluted in SFM) to a final volume of 100 ml, representing a concentration of toxin previously established as $EC 99 levels of cytopathology. The cell plates were returned to the incubator for 3.5 hr before imaging. CellTracker-labeled cells were evaluated on a Cellomics ArrayScan VTI HCS reader (Thermo Scientific) using the target acquisition mode, a 10x objective, and a sample rate of 100 objects per well. After recording all image data, the cell rounding and shrinking effects of TcdB intoxication were calculated using the CRI, a combined measure of the LWR and area parameters. The % inhibition was calculated as the ratio between the sample well and the average toxin-untreated controls after subtracting the average DMSO control values. The Z 0 value was calculated using the equation
, where s is the SD, m is the average, f indicates the DMSO control, and b indicates the toxin-untreated control. Wells that displayed potential suppression of toxin activity (>39%) were verified by visual inspection to immediately exclude false hits arising from cellular toxicity, precipitation, or autofluorescence/quenching. Hits for confirmation and follow-up assays were ordered from Microsource and Sigma as lyophilized powders. Dose-response curves were created and evaluated using Prism software (GraphPad Software).
Acute Toxicity Assay
Loss of cellular ATP as a marker of high-dose (1 nM) TcdB toxicity was measured as described for the ArrayScan screen protocol, except that CellTiter-Glo reagent (Promega) was added to the cells 3 hr post toxin challenge, and luminescence was recorded on a SpectraMax M5 plate reader.
LysoTracker Assay
Endosomal pH neutralization was assayed essentially as described by Slater et al. (2013) ; IMR-90 cells in complete EMEM were plated at 14,000 cells/well ($95% confluency). After 24 hr, the medium was changed to SFM for 60 min, then compound was added to 40 mM and incubated at 37 C for 2 hr. LysoTracker red DND-99 and Hoechst (Life Technologies) were added to 0.1 mM and 1 mM, respectively, and incubated for 60 min. Excess dye was removed by medium change, and the fluorescence at excitation/emission 574/594 was read on an Envision plate reader (Perkin Elmer). Representative cell images were taken using a Zeiss Axiovert fluorescence microscope using DAPI and Texas red filters to visualize the Hoechst and LysoTracker staining, respectively.
Cysteine Protease Assay
Inhibition of TcdB self-cleavage by its intrinsic cysteine protease activity was measured by preincubating test compounds with TcdB for 30 min, followed by addition of InsP6, and incubating the reaction at 37 C for 3 hr. Cleavage was visualized by electrophoresing the samples on SDS polyacrylamide gels and staining with Coomassie blue R250.
TcdB Aggregation and Cysteine Protease Activation Assay
Recombinant full-length TcdB in PBS/5 mM DTT was mixed with 50 mM compound and incubated for 3 hr at room temperature. The samples were then centrifuged at 10,000 3 g for 10 min before mixing the supernatant with an equal volume of Laemmli sample buffer, electrophoresed on 4%-20% SDS polyacrylamide gels, and stained with Coomassie R250.
Glucosyltransferase Western Blot Assays
For each reaction containing 10 nM GTD and 25 mM UDP-glucose, compound was added (1% final DMSO) and preincubated for 30 min, followed by addition of gstRac1 to 0.8 mM. The reaction was stopped after a 60 min reaction time with an equal volume of Laemmli loading buffer plus b-mercaptoethanol (Bio-Rad), heated to 90 C before immediately loading on an SDS polyacrylamide gel. Following electrophoresis, samples were transferred to nitrocellulose using an iBlot device (Invitrogen), blocked with 5% milk/Tris-buffered saline (TBS), and probed with a 1/1,000 dilution of either Mab102 or anti-GST antibodies. Following an overnight incubation with the primary antibody, the blot was washed with TBS/0.1% Tween20 and incubated with a 1/5,000 dilution of anti-mouse horseradish peroxidase for 60 min. After the final washes in Tris-buffered saline with Tween 20, chemiluminescent detection was carried out using SuperSignal substrate (Thermo Pierce) and exposing to BioMax MR film (Kodak).
Differential Scanning Fluorometry
Differential scanning fluorometry was performed in a similar manner as described previously (Niesen et al., 2007) . TcdB protein was diluted in phosphate buffer (100 mM KPO 4 , 150 mM NaCl [pH 7]) containing 5x SYPRO Orange (Invitrogen) and a serial dilution of test compound. A Bio-Rad CFX96 qRT-PCR thermocycler was used to establish a temperature gradient from 15 C to 95 C in 30 s increments, while simultaneously recording the increase in SYPRO Orange fluorescence as a consequence of binding to hydrophobic regions exposed on unfolded proteins. The Bio-Rad CFX Manager 3.1 software was used to integrate the fluorescence curves to calculate the melting point.
TcdB Cell Surface Binding
TcdB binding to Vero cells was assessed as described earlier with minor modifications (Orth et al., 2014) . Briefly, 100 ng/ml TcdB was preincubated with 200 mg/ml bezlotoxumab, 40 mM methyl cholate, or 40 mM cholic acid for 45 min in Eagle's MEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 U/ml streptomycin. Mixtures were then added to confluent cultures of prechilled Vero cells and plates were incubated on ice for 45 min. Plates were then washed three times with cold PBS and harvested by scraping. Membranes were isolated and samples analyzed by Western blot as previously described (Orth et al., 2014) .
SPA
The TcdB GTD was incubated at a final concentration of 2 nM in glucosylation buffer (50 mM HEPES [pH 7.5], 100 mM KCl, 4 mM MgCl 2 , 1 mM MnCl 2 ) with various concentrations of inhibitor in a final volume of 20 ml in a 96-well PCR plate (Sarstedt). Reactions were started with the simultaneous addition of 2.5 ml each of GST-Rac1 (20 mM final) and a mixture of 0.5 mCi of UDP-[6-3 H]-glucose (0.5 mM final) and cold UDP-glucose (19.5 mM final). Reactions were allowed to proceed at room temperature for 30 min, before being transferred to a white, polystyrene 96-well plate (Costar) containing a mixture of 250 ml of 0.5 M EDTA and glutathione-coated polyvinyltoluene beads (PerkinElmer) at a final concentration of 2 mg/ml. The beads were allowed to settle overnight at room temperature to increase the signal to background ratio before being analyzed on a TopCount NXT scintillation counter (PerkinElmer). Results were analyzed using GraphPad Prism 5.0.
UDP-Glo UDP-Glucose Hydrolase Assay (Promega) Experiments were performed as per the manufacturer's instructions. Briefly, 100 nM of GTD enzyme was incubated in glucosylation buffer (see above) with various concentrations of inhibitor in a final volume of 16 ml. Reactions were started with the addition of 4 ml of UDP-glucose (50 mM final). Reactions were allowed to proceed at room temperature for 15 min. To stop the reaction, 10 ml was removed and added to a white, polystyrene 96-well half-area plate (Costar) containing 10 ml of UDP detection reagent. Plates were incubated at room temperature for 1 hr, then luminescence was recorded on a SpectraMax M5e plate reader (Molecular Devices) with an integration time of 750 ms. Results were analyzed with SoftMax Pro 6.2.2 and GraphPad Prism 5.0.
Kinetic Measurements
The UDP-Glo assay was used to measure hydrolase activity as described above at various concentrations of UDP-glucose (50, 25, 12.5, 6.25, 3.125 , and 1.56 mM) at various time points for 90 min, at various concentrations of phloretin (60, 40, and 0 mM). Time courses were fit to the nonlinear function [P] = v 0 /h(1 À e Àht ), where P is the product, v 0 is the initial velocity, and h is the relaxation constant of v 0 that describes nonlinearity in progress curves (Cao and De La Cruz, 2013) . Initial velocities were plotted against UDP-glucose concentrations and fit to the Michaelis-Menten equation v = V max [S]/K m + [S], to determine the kinetic constants K m and V max for each concentration of phloretin. Supplemental Information includes one table and three 
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